晚期肝细胞癌的血液肿瘤突变负担特征及预测因素。
Profile and Predictors of Blood Tumor Mutational Burden in Advanced Hepatocellular Carcinoma.
机构信息
Massachusetts General Hospital and Harvard Medical School, Division of Hematology-Oncology, Boston, MA, USA.
University of Texas Southwestern Medical Center, Division of Hematology-Oncology, Dallas, TX, USA.
出版信息
Oncologist. 2022 Nov 3;27(11):e908-e911. doi: 10.1093/oncolo/oyac189.
Advanced hepatocellular carcinoma (HCC) is responsive to immune checkpoint inhibitors, but there are currently no known biomarkers to predict treatment benefit. Blood TMB (bTMB) estimation via circulating tumor DNA (ctDNA) profiling can provide a convenient means to estimate HCC TMB. Here we provide the first landscape of bTMB in advanced HCC using a commercially available next-generation sequencing assay, show that it is approximately three times as high as matched tissue TMB, and show that bTMB correlates with NAFLD cirrhosis etiology and the presence of genomic alterations in HTERT and TP53. These results lay the foundation for subsequent studies evaluating bTMB as an immune therapy predictive biomarker in HCC.
晚期肝细胞癌 (HCC) 对免疫检查点抑制剂有反应，但目前尚无预测治疗效果的已知生物标志物。通过循环肿瘤 DNA (ctDNA) 分析进行血液 TMB (bTMB) 估计可以提供一种方便的方法来估计 HCC TMB。在这里，我们使用市售的下一代测序检测方法首次提供了晚期 HCC 中 bTMB 的全景图，结果表明 bTMB 比匹配的组织 TMB 高约三倍，并表明 bTMB 与 NAFLD 肝硬化病因以及 HTERT 和 TP53 中的基因组改变有关。这些结果为随后的研究奠定了基础，这些研究将评估 bTMB 作为 HCC 免疫治疗预测生物标志物的价值。
Zotero 插件